Industry veteran, Michael Glynn, has joined CANbridge Life Sciences' advisory team, where he will provide leadership, direction and input on the CANbridge commercial strategy and planning as the company prepares for its first commercial launch.

CANbridge Life Sciences is a biopharmaceutical company focused on developing Western drug candidates in China and North Asia.

Glynn is a seasoned global executive with over 40 years of general management and commercialization experience in Asia Pacific, Japan, the Middle East, Latin America and the United States.

Most recently, Glynn was serving as the Senior Vice President, Global Commercial Operations, for Synageva BioPharma, where he managed global commercial infrastructure development and implementation for their rare disease lead product launch.

His prior experience covers decades of global commercial strategic, leadership and operations activities in medical products and devices in multiple territories, including at Genzyme Corporation, where he rose to the position of Senior Vice President and Regional President, Japan and Asia Pacific. While at Genzyme, MGlynn directed Genzyme's Japan-Asia Pacific business, growing $186 million in 2007 to $500 million in 2011.